518 related articles for article (PubMed ID: 36395603)
1. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
[TBL] [Abstract][Full Text] [Related]
2. Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection.
Li H; Sun M; Lei F; Liu J; Chen X; Li Y; Wang Y; Lu J; Yu D; Gao Y; Xu J; Chen H; Li M; Yi Z; He X; Chen L
Antiviral Res; 2024 Apr; 224():105841. PubMed ID: 38408645
[TBL] [Abstract][Full Text] [Related]
3. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
[TBL] [Abstract][Full Text] [Related]
4. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
[TBL] [Abstract][Full Text] [Related]
5. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
[TBL] [Abstract][Full Text] [Related]
6. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS).
St John SE; Tomar S; Stauffer SR; Mesecar AD
Bioorg Med Chem; 2015 Sep; 23(17):6036-48. PubMed ID: 26190463
[TBL] [Abstract][Full Text] [Related]
7. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
8. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent covalent SARS-CoV-2 3CL
Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
[TBL] [Abstract][Full Text] [Related]
10. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
11. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
[TBL] [Abstract][Full Text] [Related]
12. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
13. [Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL
Shang ZP; Yi Y; Yu R; Fan JJ; Huang YX; Qiao X; Ye M
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):907-919. PubMed ID: 36241233
[TBL] [Abstract][Full Text] [Related]
14. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
Viruses; 2021 May; 13(5):. PubMed ID: 34068686
[TBL] [Abstract][Full Text] [Related]
15. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
Ahmad B; Batool M; Ain QU; Kim MS; Choi S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
[TBL] [Abstract][Full Text] [Related]
17. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
[TBL] [Abstract][Full Text] [Related]
18. Computational Screening of Inhibitory Compounds for SARS-Cov-2 3CL Protease with a Database Consisting of Approved and Investigational Chemicals.
Miwa K; Guo Y; Hata M; Yamamoto N; Hoshino T
Chem Pharm Bull (Tokyo); 2023; 71(5):360-367. PubMed ID: 37121686
[TBL] [Abstract][Full Text] [Related]
19. Amentoflavone derivatives significantly act towards the main protease (3CL
Dey D; Hossain R; Biswas P; Paul P; Islam MA; Ema TI; Gain BK; Hasan MM; Bibi S; Islam MT; Rahman MA; Kim B
Mol Divers; 2023 Apr; 27(2):857-871. PubMed ID: 35639226
[TBL] [Abstract][Full Text] [Related]
20. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
